News
Cell-free DNA-based liquid biopsies showed promise for monitoring response to pancreatic cancer therapies and making ...
The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback